SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin to expand its Vadodara facility: Report

03 Mar 2014 Evaluate

In a bid to make bulk drugs for cardiac, anti-infectives, anti-tuberculosis, neurology and other segments, Lupin is reportedly planning to expand its Vadodara facility. In this regard, the company will invest around Rs 270 crore.

The Dabhasa plant of Lupin near Vadodara is one of the leading bulk drug manufacturing sites for the company. The Dabhasa plant is one of our major active pharmaceutical ingredient manufacturing sites which also exports. It is a US Food and Drug Administration (USFDA) approved facility.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally.

Lupin Share Price

2419.10 -30.70 (-1.25%)
30-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 2000.75
Dr. Reddys Labs. 1144.35
Cipla 1466.00
Lupin 2419.10
Zydus Lifesciences 1115.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: